Barclays PLC Avidity Biosciences, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Barclays PLC holds 255,699 shares of RNA stock, worth $8.14 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

255,699

Previous 255,699 -0.0%

Holding current value

$8.14 Million

Previous $11.7 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$37.21 - $48.14 $6.1 Million - $7.89 Million	163,905 Added 178.56%	255,699 $11.7 Million
Q2 2024 Aug 14, 2024	SELL	$22.73 - $40.85 $730,814 - $1.31 Million	-32,152 Reduced 25.94%	91,794 $3.75 Million
Q1 2024 May 15, 2024	SELL	$9.16 - $25.52 $679,378 - $1.89 Million	-74,168 Reduced 37.44%	123,946 $3.16 Million
Q4 2023 Feb 15, 2024	BUY	$4.87 - $9.37 $42,826 - $82,399	8,794 Added 4.65%	198,114 $1.79 Million
Q3 2023 Nov 07, 2023	SELL	$6.3 - $11.35 $1.98 Million - $3.57 Million	-314,350 Reduced 62.41%	189,320 $1.21 Million
Q2 2023 Aug 03, 2023	BUY	$10.62 - $17.34 $1.4 Million - $2.29 Million	132,047 Added 35.53%	503,670 $5.59 Million
Q1 2023 May 04, 2023	SELL	$15.35 - $25.65 $74,554 - $124,582	-4,857 Reduced 1.29%	371,623 $5.71 Million
Q4 2022 Feb 13, 2023	BUY	$10.06 - $22.66 $2.08 Million - $4.68 Million	206,715 Added 121.77%	376,480 $8.36 Million
Q3 2022 Nov 03, 2022	BUY	$15.46 - $23.43 $614,225 - $930,873	39,730 Added 30.55%	169,765 $2.77 Million
Q2 2022 Aug 12, 2022	BUY	$11.18 - $20.5 $879,966 - $1.61 Million	78,709 Added 153.35%	130,035 $1.89 Million
Q1 2022 May 16, 2022	BUY	$14.2 - $23.78 $728,829 - $1.22 Million	51,326 New	51,326 $947,000

Others Institutions Holding RNA

# of Institutions

255

Shares Held

107M

Call Options Held

224K

Put Options Held

161K

View Full List

About Avidity Biosciences, Inc.

Ticker RNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,127,000
Market Cap $1.66B
Description
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...

More about RNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account